PASSARO, ANTONIO
 Distribuzione geografica
Continente #
NA - Nord America 385
EU - Europa 103
AS - Asia 48
AF - Africa 4
OC - Oceania 1
SA - Sud America 1
Totale 542
Nazione #
US - Stati Uniti d'America 381
IT - Italia 55
SE - Svezia 22
IN - India 20
CN - Cina 16
SG - Singapore 11
FI - Finlandia 10
CA - Canada 4
PL - Polonia 4
DE - Germania 3
GB - Regno Unito 3
TG - Togo 3
IE - Irlanda 2
UA - Ucraina 2
AR - Argentina 1
BG - Bulgaria 1
IR - Iran 1
NZ - Nuova Zelanda 1
RS - Serbia 1
ZA - Sudafrica 1
Totale 542
Città #
Fairfield 71
Cambridge 35
Seattle 35
Ashburn 32
Woodbridge 29
Chandler 28
Houston 21
Wilmington 17
Beijing 15
Princeton 13
Rome 11
Plano 9
San Paolo di Civitate 8
Ann Arbor 6
Cagliari 6
Lawrence 6
Singapore 6
Dearborn 4
Millbury 4
New York 4
Fremont 3
Helsinki 3
Lomé 3
Toronto 3
Andover 2
Boston 2
Catania 2
Dublin 2
Redmond 2
San Diego 2
Somma Lombardo 2
Auckland 1
Bologna 1
Des Moines 1
Federal 1
Jacksonville 1
Lodz 1
Milan 1
Montréal 1
Muizenberg 1
New Delhi 1
Ningbo 1
Norwalk 1
Polska 1
Pune 1
San Mateo 1
Santi Cosma E Damiano 1
Sassuolo 1
Simi Valley 1
Sofia 1
Southend 1
Washington 1
Totale 407
Nome #
Antiangiogenic agents are ineffective to increase complete response rate in MRCC:A meta-analysis 79
Multimodality Treatment of Gynecomastia in Patients Receiving Antiandrogen Therapy for Prostate Cancer in the Era of Abiraterone Acetate and New Antiandrogen Molecules 77
Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer 68
The Impact of Chemotherapy on the Lymphatic System in Thoracic Oncology 65
Molecular and Clinical Analysis of Predictive Biomarkers in Non-Small-Cell Lung Cancer 59
Delivery optimization of erlotinib according to toxicity: may clinical practice go beyond research? 57
Second-line treatment of non-small-cell lung cancer: chemotherapy or tyrosine kinase inhibitors? 54
Erlotinib and gefitinib for elderly patients with advanced non-small-cell lung cancer. 53
null 30
Valutazione prospettica di una signature circolante come fattore predittivo di risposta nel carcinoma polmonare non a piccole cellule (NSCLC) trattato con Nivolumab in seconda linea 12
Totale 554
Categoria #
all - tutte 1.318
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1.318


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020142 22 6 0 10 14 16 16 13 14 20 7 4
2020/202134 4 4 1 2 2 3 0 5 7 2 4 0
2021/202284 1 6 13 0 9 4 0 11 4 10 11 15
2022/2023103 22 21 8 6 13 11 2 5 9 1 2 3
2023/202446 5 3 2 3 6 10 0 9 0 1 2 5
2024/20252 2 0 0 0 0 0 0 0 0 0 0 0
Totale 554